Oncternal Therapeutics, Inc. (ONCT)
Dec 3, 2024 - ONCT trading suspended
0.5266
-0.1670 (-24.12%)
Inactive · Last trade price on Dec 2, 2024
Oncternal Therapeutics Revenue
Oncternal Therapeutics had revenue of $494.00K in the quarter ending September 30, 2024, with 175.98% growth. This brings the company's revenue in the last twelve months to $2.16M, up 227.92% year-over-year. In the year 2023, Oncternal Therapeutics had annual revenue of $785.00K, down -47.32%.
Revenue (ttm)
$2.16M
Revenue Growth
+227.92%
P/S Ratio
0.72
Revenue / Employee
$72,033
Employees
30
Market Cap
1.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 785.00K | -705.00K | -47.32% |
| Dec 31, 2022 | 1.49M | -2.83M | -65.47% |
| Dec 31, 2021 | 4.32M | 940.00K | 27.85% |
| Dec 31, 2020 | 3.38M | 950.00K | 39.18% |
| Dec 31, 2019 | 2.43M | -96.00K | -3.81% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionONCT News
- 4 months ago - Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations - GlobeNewsWire
- 8 months ago - Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC - GlobeNewsWire
- 1 year ago - Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results - GlobeNewsWire
- 1 year ago - Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results - GlobeNewsWire
- 1 year ago - Oncternal Therapeutics to Present in JonesTrading Healthcare Summit - GlobeNewsWire
- 1 year ago - Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 1 year ago - Oncternal Therapeutics, Inc. (ONCT) Q1 2024 Earnings Call Transcript - Seeking Alpha